检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:蒋兰 杨匹容 李娟[2] Jiang Lan;Yang Pirong;Li Juan(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,Sichuan,China;Department of Medical Oncology,Sichuan Clinical Research Center for Cancer,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,Affiliated Cancer Hospital of University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China)
机构地区:[1]电子科技大学医学院,成都610054 [2]四川省肿瘤临床医学研究中心,四川省肿瘤医院.研究所,四川省癌症防治中心,电子科技大学附属肿瘤医院肿瘤内科,成都610041
出 处:《肿瘤预防与治疗》2023年第9期753-758,共6页Journal of Cancer Control And Treatment
基 金:四川省医学会医学科研课题(编号:S20027)。
摘 要:肺肉瘤样癌(pulmonary sarcomatoid carcinoma,PSC)是非小细胞肺癌的一种罕见亚型,侵袭性高,预后很差。目前尚没有针对PSC的标准疗法,早期患者首选手术,无法手术者需要进一步探索有效疗法,因为PSC对传统化疗及放射治疗不敏感。现推荐对PSC患者进行基因测序及分子生物标志物检测,因为针对特定基因突变患者的靶向治疗可能是有效的,如MET14外显子跳跃突变,程序性死亡配体-1过表达使得免疫治疗在PSC的治疗中也展示出巨大的潜力。由于PSC的高度血管侵袭性,抗血管生成治疗也是潜在有效治疗手段。本文除了总结现有常规治疗手段在PSC中的疗效,针对各种联合抗肿瘤治疗如双靶联合、免疫联合放化疗以及免疫联合抗血管生成治疗、双免联合等在PSC中的最新进展,也进行了详细的阐述。Pulmonary sarcomatoid carcinoma(PSC)is a rare subtype of non-small cell lung cancer,with a highly aggressive nature and poor prognosis.There is no standard therapy for PSC.Surgery is preferred for early-stage patients,and further exploration of effective therapies is needed for inoperable patients,for PSC is not sensitive to conventional chemotherapy and radiation therapy.Genetic sequencing and molecular biomarker testing are recommended for patients with PSC,because targeted therapy for patients with specific genetic mutations,such as the MET 14 exon skipping mutation,may be effective.Programmed death ligand 1 overexpression also allows immunotherapy to show great potential in the treatment of PSC.Due to high vascular aggression of PSC,anti-angiogenic therapy is also a potential effective treatment.In addition to summarizing the efficacy of existing conventional therapies in PSC,this review also summarizes current advances in various antitumor combination therapies such as dual target combination,immunotherapy combined with chemoradiotherapy,immunotherapy combined with anti-angiogenic therapy and dual immune combination in PSC.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.166